Compare MIGI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIGI | TVRD |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 29.1M |
| IPO Year | 2013 | N/A |
| Metric | MIGI | TVRD |
|---|---|---|
| Price | $7.41 | $3.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | ★ 1.2M | 49.0K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,754,085.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $2.75 |
| 52 Week High | $15.80 | $43.65 |
| Indicator | MIGI | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 73.98 | 44.85 |
| Support Level | $3.95 | $2.75 |
| Resistance Level | $15.80 | $3.50 |
| Average True Range (ATR) | 1.06 | 0.24 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 99.79 | 45.33 |
Mawson Infrastructure Group Inc is focused on digital infrastructure platforms. It designs, builds and operates next-generation digital infrastructure platforms for enterprise customers and for its own purposes. The company provides services spanning AI, HPC, digital assets including Bitcoin mining, and other intensive compute applications. The company delivers both self-mining operations and colocation services to enterprise customers with a vertically integrated infrastructure model built for scalability and efficiency. The company also has an energy management business, which utilizes software and analysis, to generate revenue by participating in energy management programs. It operates as one energy management and digital asset mining segment.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.